- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07601724
The Impact of Volume Overload on Obstructive Sleep Apnea in Patients With Congestive Heart Failure
The goal of this observational study is to learn how removing extra fluid from the body (diuresis) affects sleep apnea in adults hospitalized with heart failure.
The main questions it aims to answer are:
Does sleep apnea severity improve after fluid removal? Is the improvement in sleep apnea related to the amount of fluid removed? Do changes in neck size reflect changes in sleep apnea severity?
Participants admitted to the hospital with heart failure and fluid overload will take part in this study.
Participants will:
Use a wearable sleep monitoring device (WatchPAT) on the first night of hospitalization Use the device again after fluid removal, when the treating cardiologist determines that the patient is no longer fluid overloaded Have their neck circumference measured before and after fluid removal Have their weight and fluid balance recorded during hospitalization Have routine blood tests and clinical assessments as part of standard care
Researchers will compare each participant's results before and after fluid removal to see if sleep apnea improves and whether these changes are linked to fluid removal and changes in neck circumference.
Descripción general del estudio
Estado
Tipo de estudio
Inscripción (Estimado)
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Itshak Amsalem, MD
- Número de teléfono: +972508229454
- Correo electrónico: itshak1a@gmail.com
Ubicaciones de estudio
-
-
-
Jerusalem, Israel
- Reclutamiento
- Shaare Zedek Medical Center
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
- Adulto
- Adulto Mayor
Acepta Voluntarios Saludables
Método de muestreo
Población de estudio
Descripción
Inclusion Criteria:
- Adults aged 18 years or older
- Hospitalized with decompensated heart failure and clinical evidence of fluid overload
- Diagnosis of heart failure (reduced or preserved ejection fraction)
- Clinically indicated for diuretic therapy
- Able to undergo sleep apnea assessment using the WatchPAT device
- Able to provide informed consent
Exclusion Criteria:
- Known central sleep apnea as the predominant sleep-disordered breathing type
- Current treatment with continuous positive airway pressure (CPAP)
- Acute respiratory failure requiring mechanical ventilation
- Conditions preventing proper use of the WatchPAT device (e.g., severe hand or finger injury)
- Hemodynamic instability precluding participation
- Pregnancy
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
Cohortes e Intervenciones
Grupo / Cohorte |
|---|
|
Adults With Heart Failure Undergoing Diuresis
Adults hospitalized with heart failure and fluid overload who undergo standard diuretic therapy.
Participants are evaluated using sleep monitoring (WatchPAT), neck circumference measurements, and clinical assessments before diuresis (on the first night of hospitalization) and after diuresis, when the treating cardiologist determines that the patient is no longer fluid overloaded.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change in apnea-hypopnea index (AHI)
Periodo de tiempo: From first night of hospitalization to achievement of clinical euvolemia (during hospitalization), up to 30-days.
|
Change in obstructive sleep apnea severity, measured by the apnea-hypopnea index (AHI) using the WatchPAT device, between the first night of hospitalization (pre-diuresis) and after diuresis, when the treating cardiologist determines that the participant is no longer fluid overloaded
|
From first night of hospitalization to achievement of clinical euvolemia (during hospitalization), up to 30-days.
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change in oxygen desaturation index (ODI)
Periodo de tiempo: From first night of hospitalization to achievement of clinical euvolemia, up to 30-days.
|
Change in oxygen desaturation index (ODI) measured by the WatchPAT device between pre-diuresis and post-diuresis assessments
|
From first night of hospitalization to achievement of clinical euvolemia, up to 30-days.
|
|
Change in respiratory disturbance index (RDI)
Periodo de tiempo: From first night of hospitalization to achievement of clinical euvolemia, up to 30-days.
|
Change in respiratory disturbance index (RDI), defined as the number of respiratory disturbance events per hour of sleep, measured using the WatchPAT device, between the first night of hospitalization (pre-diuresis) and after diuresis, when the treating cardiologist determines that the participant is no longer fluid overloaded
|
From first night of hospitalization to achievement of clinical euvolemia, up to 30-days.
|
|
Correlation between change in respiratory disturbance index (RDI) and body weight change
Periodo de tiempo: From first night of hospitalization to achievement of clinical euvolemia, up to 30-days.
|
Correlation between the change in respiratory disturbance index (RDI), measured in events per hour using the WatchPAT device, and change in body weight measured in kilograms during hospitalization
|
From first night of hospitalization to achievement of clinical euvolemia, up to 30-days.
|
|
Correlation between change in apnea-hypopnea index (AHI) and body weight change
Periodo de tiempo: From first night of hospitalization to achievement of clinical euvolemia, up to 30 days
|
Correlation between the change in apnea-hypopnea index (AHI), defined as the number of apnea and hypopnea events per hour of sleep and measured using the WatchPAT device, and change in body weight measured in kilograms during hospitalization
|
From first night of hospitalization to achievement of clinical euvolemia, up to 30 days
|
|
Change in neck circumference
Periodo de tiempo: From admission to achievement of clinical euvolemia, up to 30 days
|
Change in neck circumference, measured in centimeters using a standardized measuring tape, between pre-diuresis (at admission) and post-diuresis assessment after the treating cardiologist determines that the participant is no longer fluid overloaded
|
From admission to achievement of clinical euvolemia, up to 30 days
|
|
Correlation coefficient between change in neck circumference and change in apnea-hypopnea index (AHI)
Periodo de tiempo: From admission to achievement of clinical euvolemia, up to 30 days
|
Correlation coefficient (unitless) describing the relationship between change in neck circumference (centimeters) and change in apnea-hypopnea index (AHI), measured in events per hour using the WatchPAT device
|
From admission to achievement of clinical euvolemia, up to 30 days
|
Colaboradores e Investigadores
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Enfermedades del Sistema Nervioso
- Enfermedades cardiovasculares
- Enfermedades cardíacas
- Enfermedades de las vías respiratorias
- Trastornos de la respiración
- Trastornos del sueño y la vigilia
- Apnea
- Trastornos del Sueño Intrínsecos
- Disomnias
- Síndromes de apnea del sueño
- Insuficiencia cardiaca
- Apnea del Sueño Obstructiva
Otros números de identificación del estudio
- 0350-24-SZMC
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Insuficiencia cardiaca
-
Region SkaneInscripción por invitaciónInsuficiencia cardíaca New York Heart Association (NYHA) Clase II | Insuficiencia cardíaca New York Heart Association (NYHA) Clase IIISuecia
-
Medical University of BialystokMedical University of Lodz; Poznan University of Medical Sciences; Nicolaus Copernicus... y otros colaboradoresTerminadoInsuficiencia Cardíaca Sistólica | Insuficiencia cardíaca con fracción de eyección reducida | Insuficiencia cardíaca Clase IV de la New York Heart Association | Insuficiencia cardíaca Clase III de la New York Heart AssociationPolonia
-
Novartis PharmaceuticalsTerminadoPacientes que completaron con éxito el período de tratamiento de 12 meses del estudio principal (receptores de Novo Heart) que estaban interesados en recibir tratamiento con EC-MPS
-
University of WashingtonAmerican Heart AssociationTerminadoInsuficiencia cardíaca, congestiva | Alteración mitocondrial | Insuficiencia cardíaca Clase IV de la New York Heart AssociationEstados Unidos